News

Lupin today announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for its Ankleshwar facility in Gujarat, India, following closure of a product specific Pre-Approval Inspection from 02 March to 07 March 2026.

Lupin today announced that it has been featured for the first time in the Dow Jones Best-in-Class (DJBIC) Indices, underscoring the company`s strong commitment to sustainable, responsible, and ethical business practices. Lupin has been listed in both the DJBIC World Index and the DJBIC Emerging Markets Index. The DJBIC World Index ranks top-performing companies globally by strong ESG performance, while the DJBIC Emerging Markets Index highlights sustainability leaders across emerging economies. Lupin was previously ranked among the top 1% globally in the S&P Global Corporate Sustainability Assessment (CSA) 2025, achieving an industry-leading score of 91/100.The Dow Jones Best-in-Class Indices recognize companies that demonstrate exceptional performance across key Environmental, Social, and Governance (ESG) parameters, based on leading S&P Global CSA scores. Inclusion in these prestigious indices reinforces Lupin`s credibility with global investors, strengthens its competitive positioning, and places the company among a distinguished group of global leaders recognized for best-in-class sustainability performance.

Lupin announced that the Board of Directors of the Company at its meeting held on 7 May 2026, inter alia, have recommended the final dividend of Rs 18 per equity Share (i.e. 900%) , subject to the approval of the shareholders.

Net profit of Lupin rose 89.04% to Rs 1460.34 crore in the quarter ended March 2026 as against Rs 772.52 crore during the previous quarter ended March 2025. Sales rose 32.90% to Rs 7391.91 crore in the quarter ended March 2026 as against Rs 5562.20 crore during the previous quarter ended March 2025.For the full year,net profit rose 62.51% to Rs 5332.84 crore in the year ended March 2026 as against Rs 3281.62 crore during the previous year ended March 2025. Sales rose 23.86% to Rs 27487.54 crore in the year ended March 2026 as against Rs 22192.11 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales7391.915562.20 33 27487.5422192.11 24 OPM %33.6323.75 -32.0723.81 - PBDT2506.131289.02 94 8805.965184.26 70 PBT2059.34895.84 130 7430.464015.00 85 NP1460.34772.52 89 5332.843281.62 63 Powered by Capital Market - Live News

Lupin has allotted 36,752 equity shares under ESOP on 04 May 2026. With this allotment, the paid up equity share capital has increased to Rs 91,44,31,726 consisting of 45,72,15,863 equity shares of Rs 2/- each.